Core Viewpoint - Oriental Bio has experienced a stock price increase of 5.11% on November 12, reaching 28.57 CNY per share, with a total market capitalization of 5.76 billion CNY, indicating a cumulative increase of 4.34% over three consecutive days [1] Company Overview - Zhejiang Oriental Gene Biological Products Co., Ltd. was established on December 1, 2005, and went public on February 5, 2020. The company specializes in the research, production, and sales of in vitro diagnostic products, with 97.99% of its revenue coming from diagnostic reagents and 2.01% from other supplementary sources [1] Shareholder Analysis - The top circulating shareholder of Oriental Bio includes a fund from Rongtong Fund, which reduced its holdings by 1.7 million shares in the third quarter, now holding 2.8 million shares, representing 1.39% of the circulating shares. The fund has gained approximately 3.89 million CNY in floating profit today and 3.16 million CNY during the three-day increase [2] Fund Performance - The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) has a total scale of 1.816 billion CNY and has achieved a year-to-date return of 15.36%, ranking 5146 out of 8147 in its category. Over the past year, it has returned 1.86%, ranking 7321 out of 8056, and since inception, it has returned 178.7% [2] Fund Holdings - The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) has Oriental Bio as its tenth largest holding, with 2.98% of the fund's net value allocated to this stock. The fund manager, Wan Minyuan, has been in position for 9 years and 81 days, with the best return during his tenure being 143.42% and the worst being -21.5% [3]

Group 1 - The outbreak of respiratory syncytial virus (RSV) in Tianjin has peaked earlier than expected, with flu activity rising in southern provinces and most northern provinces during the 44th week of 2025 [1] - The latest flu monitoring report from the National Disease Control indicates an increase in flu cases, highlighting the need for vigilance against RSV alongside influenza [4] Group 2 - In the A-share market, flu-related stocks are experiencing significant activity, with Aipeng Medical rising over 10%, and other companies like Panlong Pharmaceutical hitting the daily limit, indicating strong investor interest [2] - The detection rates for severe acute respiratory infections show that rhinovirus (10.6%), RSV (8.5%), and influenza virus (4.2%) are the top three pathogens, emphasizing the impact of RSV on public health [4]

Core Viewpoint - The A-share market is seeing active trading in flu-related stocks, driven by an early peak in respiratory syncytial virus (RSV) and flu activity in China, as reported by the National Disease Control [1][2]. Group 1: Market Activity - Aipeng Medical has risen over 10%, while Panlong Pharmaceutical has reached a 10% limit up, with other companies like Rejing Bio and Dongfang Bio also seeing significant gains [1]. - The latest flu monitoring report indicates an increase in flu activity in southern provinces and a rise in northern provinces during the 44th week of 2025 [1]. Group 2: Key Data on Stocks - Aipeng Medical (300753) has a market cap of 3.969 billion and a year-to-date increase of 79.09% [2]. - Panlong Pharmaceutical (002864) has a market cap of 3.788 billion and a year-to-date increase of 18.84% [2]. - Rejing Bio (688068) has a market cap of 14 billion and a year-to-date increase of 144.44% [2]. - Dongfang Bio (688298) has a market cap of 5.836 billion with a slight year-to-date decrease of 1.30% [2]. - Other notable stocks include Te Yi Pharmaceutical (002728) with a market cap of 6.961 billion and a year-to-date increase of 52.45% [2].

Core Viewpoint - Oriental Bio's stock price has shown fluctuations, with a recent increase of 2.10% to 27.75 CNY per share, while the company has experienced a year-to-date decline of 5.39% [1] Financial Performance - For the period from January to September 2025, Oriental Bio reported a revenue of 672 million CNY, reflecting a year-on-year growth of 2.16% [2] - The company recorded a net profit attributable to shareholders of -213 million CNY, which is an improvement of 18.89% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Oriental Bio was 13,300, a decrease of 3.93% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.09% to 15,170 shares [2] Dividend Distribution - Since its A-share listing, Oriental Bio has distributed a total of 1.607 billion CNY in dividends, with 336 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.8 million shares, a decrease of 1.7001 million shares from the previous period [3] - Hong Kong Central Clearing Limited is the sixth largest shareholder, with 1.4675 million shares, an increase of 139,400 shares [3] - The Southern Science and Technology Innovation Board 3-Year Open Mixed Fund holds 780,900 shares, unchanged from the previous period [3]

Core Viewpoint - Oriental Bio's stock price has shown fluctuations, with a recent increase of 2.05% and a year-to-date decline of 6.75%, indicating potential volatility in the market [1] Financial Performance - For the period from January to September 2025, Oriental Bio reported a revenue of 672 million yuan, reflecting a year-on-year growth of 2.16% [2] - The company experienced a net profit attributable to shareholders of -213 million yuan, which is an improvement of 18.89% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Oriental Bio was 13,300, a decrease of 3.93% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.09% to 15,170 shares [2] Dividend Distribution - Since its A-share listing, Oriental Bio has distributed a total of 1.607 billion yuan in dividends, with 336 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.8 million shares, a decrease of 1.7001 million shares from the previous period [3] - Hong Kong Central Clearing Limited is the sixth largest shareholder, increasing its holdings by 139,400 shares to 1.4675 million shares [3] - The Southern Science and Technology Innovation Board 3-Year Open Mixed Fund maintained its holding of 780,900 shares, while the Medical Device ETF entered as a new shareholder with 757,900 shares [3]

Core Viewpoint - The company, 东方生物, is experiencing a slight decline in stock price and is preparing for an upcoming shareholder meeting to elect a new independent director and discuss various corporate matters [1][4]. Company Announcements - 东方生物 will hold its second extraordinary general meeting of shareholders on November 20, 2025, to vote on the election of independent director 陈军泽 and adjustments to the specialized committees [1][4]. - The meeting will utilize a combination of on-site and online voting, with the record date set for November 13, 2025 [1]. - The company has received multiple medical device registration certificates for its subsidiary, 上海万子健, including test kits for gastrin-17 and NT-proBNP, which are used for diagnosing atrophic gastritis and heart failure [2][4]. Independent Director Nomination - 陈军泽 has been nominated as a candidate for independent director, with qualifications that meet regulatory requirements, including over five years of relevant work experience and no conflicts of interest [3][4]. - The nomination committee has reviewed and approved his qualifications, and he will also serve on several specialized committees if elected [2][3].

Group 1 - The core point of the article is that Dongfang Biological (688298) has completed the main construction of its project in Hainan Free Trade Zone, which is focused on the research and development of biological products [1] - The subsidiary, Hainan Wanzijian Testing Laboratory Co., Ltd., aims to engage in technology research and development, technical consulting, and the introduction, transformation, and transfer of foreign technological achievements [1]

Core Viewpoint - Dongfang Biological (688298.SH) has established a subsidiary in Hainan Free Trade Zone, focusing on the research and development of biological products and related technology services [1] Group 1 - The subsidiary, Hainan Wanzijian Inspection Laboratory Co., Ltd., aims to engage in technology research and consulting, as well as the introduction, transformation, and transfer of foreign technological achievements [1] - The main construction work for the Hainan project has been completed [1]

Core Viewpoint - Dongfang Biological (688298.SH) has established a subsidiary, Hainan Wanzijian Inspection Laboratory Co., Ltd., in the Hainan Free Trade Zone, focusing on the research and development of biological products and related services [1] Group 1 - The subsidiary aims to engage in technology research and development, technical consulting, and the introduction, transformation, and transfer of foreign technological achievements [1] - The main construction work for the Hainan project has been completed [1]

浙江东方基因生物制品股份有限公司 2025 年第二次临时股东会 证券简称：东方生物 证券代码：688298 浙江东方基因生物制品股份有限公司 2025 年第二次临时股东会会议资料 2025 年 11 月 1 浙江东方基因生物制品股份有限公司 2025 年第二次临时股东会 浙江东方基因生物制品股份有限公司 2025 年第二次临时股东会会议须知 为维护浙江东方基因生物制品股份有限公司（以下简称"公司"）全体股东 的合法权益，确保股东会的正常秩序和议事效率，保证股东会如期、顺利召开， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规 则》《浙江东方基因生物制品股份有限公司章程》《浙江东方基因生物制品股份 有限公司股东会议事规则》等相关规定，特制定本股东会会议须知。 一、为保证本次股东会的严肃性和正常秩序，切实维护与会股东（或股东代 表）的合法权益，除出席会议的股东（或股东代表），列席会议的公司董事、高 级管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入 会场。 二、出席会议的股东（或股东代表）须在会议召开前 30 分钟到会议现场办 理签到手续，并按股东会通知的相关要求，出示 ...